Trial Profile

A Randomised, Multi-Center Study of Docetaxol Plus Capecitabine or Cisplatin in Anthracycline-Pretreated Patients With Advanced Breast Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 27 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Capecitabine (Primary) ; Cisplatin (Primary) ; Docetaxel (Primary)
Indications Advanced breast cancer; Triple negative breast cancer
Focus Therapeutic Use

Most Recent Events

06 Dec 2011 Primary endpoint 'Objective-clinical-response-rate' has been met.
06 Dec 2011 Results presented at the 34th Annual San Antonio Breast Cancer Symposium.
06 Dec 2011 Planned number of patients changed to 120, and actual to 53 as reported at the 34th Annual San Antonio Breast Cancer Symposium.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com